TICKERNERD
Menu
TELOTELOHealthcare · Biotechnology

TELO Stock Forecast: Telomir Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.12
−0.88% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 21 Aug 2026 — in the weakest quartile.

Market cap
$77.7M
Ticker Nerd rank
13 / 100
Median analyst target
—
Analysts covering
0
Total return, dividends reinvested
1W
+2.8%
1M
+3.7%
YTD
−15.8%
1Y
−25.3%
From 52W high
−42.0%
From 52W low
+21.9%
$0.92
$1.93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TELO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Telomir Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Accruals
53
Growth
41
Value
39
Volatility
29
Revisions
25
Momentum
13
Issuance
13
Quality
10

Size (78): Smaller than most of the companies we track.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TELO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.10$1.20$1.30$1.40$1.50$1.60$1.70Oct 25Jan 26Apr 26Jul 26TELO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TELO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Telomir Pharmaceuticals, Inc. (TELO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.4×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
7.8×

Cheaper than 13% of US stocks

EV / EBITDA
−7.0×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−213.1%

Higher than 7% of US stocks

Return on assets
−122.8%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TELO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TELOTelomir Pharmaceuticals, Inc.$77.7M
13
ANVSAnnovis Bio, Inc.$77.4M
26
NRXSNeurAxis, Inc.$76.2M
54
GOSSGossamer Bio, Inc.$75.6M
54
ELTXElicio Therapeutics, Inc.$79.9M
38
CINGCingulate, Inc.$80.7M
28
VRCAVerrica Pharmaceuticals, Inc.$82.8M
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Telomir Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TELO news & analysis

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

GlobeNewsWire · 10 Aug 2026positive

Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that its candidate Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The announcement highlights the research findings from the publication.

Why it matters — This provides scientific validation for Telomir-Zn's therapeutic potential in two cancer types, which is directly relevant to the company's pipeline for TELO watchers.

FAQ

Frequently asked questions about TELO stock

How does Ticker Nerd's model rank TELO?

As at 21 Aug 2026, Telomir Pharmaceuticals, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

What is the TELO stock forecast for 2030?

No analyst covering Telomir Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELO are extrapolating price history, which says nothing about the business.

How has TELO stock performed over the past year?

Telomir Pharmaceuticals, Inc. returned -25.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Telomir Pharmaceuticals, Inc. do?

Telomir Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions, specializing in the field of oncology and autoimmune diseases.

What is the latest news on TELO?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models". Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that its candidate Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The announcement highlights the research findings from the publication.

Company

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions, specializing in the field of oncology and autoimmune diseases. The company's primary objective is to discover and bring to market advanced medicines aimed at improving patient outcomes. Telomir Pharmaceuticals Inc. is actively engaged in research and development of cutting-edge therapies, leveraging novel mechanisms of action to address unmet medical needs. The company operates in the dynamic healthcare sector, which plays a critical role in diagnosing, treating, and preventing complex diseases. Its research initiatives include a robust pipeline of drug candidates at various stages of clinical trials, emphasizing precision medicine and targeted treatment approaches. Telomir Pharmaceuticals Inc. collaborates with leading medical institutions and leverages advanced biotechnology to accelerate the development processes. In the financial market, Telomir Pharmaceuticals Inc. represents the biotechnology and pharmaceutical industry, contributing to the growing landscape of healthcare innovations. By advancing its drug development programs, the company holds an essential role in shaping future therapeutic modalities, impacting both healthcare professionals and patients worldwide.

CEO Mr. Erez Aminov · 1 employees · United States · https://telomirpharma.com